ライソゾーム病治療の世界市場

ライソゾーム病治療の世界市場は2030年までに112億米ドルに達する見込み

2024年に82億米ドルと推定されるライソゾーム病治療の世界市場は、2024～2030年の分析期間においてCAGR 5.4%で成長し、2030年には112億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるムコ多糖症疾患は、CAGR 6.9%を記録し、分析期間終了時には44億米ドルに達すると予測されます。ポンペス症候群疾患セグメントの成長率は、分析期間中CAGR 4.1%と推定されます。

米国市場は22億米ドルと推定、中国はCAGR 8.8％で成長予測

米国のライソゾーム病治療市場は2024年に22億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.8%で推移し、2030年には市場規模が23億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.4％と予測されています。欧州では、ドイツがCAGR 3.5%で成長すると予測されています。

世界のライソゾーム病治療市場- 主要動向と促進要因のまとめ

現代の治療においてライソゾーム病治療の重要性が高まっている理由とは？

ライソゾーム貯蔵障害（LSD）としても知られるライソゾーム病は、体内の細胞内で様々な物質を分解する特定の酵素の機能不全や欠落に起因する稀な遺伝子疾患群です。これらの物質がリソソーム内に蓄積すると、細胞障害が進行し、重要な臓器や器官に影響を及ぼします。歴史的に、LSDの診断と治療は限定的であり、患者は著しい障害と寿命の減少を伴う人生に直面することになります。しかし、診断、バイオテクノロジー、治療開発における最近の動向は、このような複雑な病態を抱える人々の見通しを一変させ始めています。希少疾患研究のエコシステムにおいて、精密医療や患者個別ケアへの幅広いシフトを反映し、ライソゾーム病治療が牽引役となっています。世間一般の認知度の向上、患者団体によるアドボカシー、希少疾病用医薬品の優遇措置などが、この分野への注目と投資の拡大に寄与しています。その結果、情勢は、ほとんど治療不可能な疾患から、製薬業界において最も活発に研究されている希少疾患のひとつへと変遷しました。ゴーシェ病、ファブリー病、ポンペ病、各種ムコ多糖症（MPS）などは現在、遺伝子および酵素補充研究の最前線にあります。これらの生命を脅かす疾患への対応が急務であることと、遺伝子治療や生物製剤の技術革新が急速に進んでいることが相まって、ライソゾーム病治療は現代の希少疾患治療薬の進歩における重要なフロンティアとして位置づけられています。

ライソゾーム病治療における科学的進歩と治療方法はどのように進化しているか？

酵素補充療法（ERT）、基質還元療法（SRT）、遺伝子治療、薬理学的シャペロンなどの画期的な開発により、ライソゾーム病の治療法は急速に進歩しています。ERTは最も確立されたアプローチであり、ライソゾーム機能を回復させるために欠損酵素の合成版を静脈注射します。ERTは特定の症状を緩和し、生活の質を改善するのに有効であるが、血液脳関門を通過できないため、神経学的症状への対応に苦慮することが多いです。この限界が、AAV（アデノ随伴ウイルス）などのウイルスベクターを用いて治療遺伝子を患者の細胞に直接導入する遺伝子治療の技術革新に拍車をかけています。これらの遺伝子治療は、患者自身の細胞が必要な酵素を産生できるようにすることによって、長期的な解決策を提供することを目的としており、全身および中枢神経系への治療に希望を与えるものです。薬理学的シャペロンは、ミスフォールドした酵素を安定化させ、その機能を向上させるという、もう一つの新たな選択肢です。一方、基質低減療法は、有害な基質の産生を制限することによって、その蓄積を減少させることを目的としており、酵素に焦点を当てたアプローチを補完する戦略を提供しています。CRISPR遺伝子編集、エクソソームベースのデリバリー、ナノメディシンの進歩も、ライソゾーム機能障害をより正確にターゲットとする将来の可能性のあるツールとして研究されています。重要なことは、次世代シークエンシングやバイオマーカー同定などの診断能力の向上により、LSDサブタイプの早期かつ正確な同定が可能となり、個別化治療レジメンがより実行可能になってきていることです。こうした治療法の進化により、医師や研究者が利用できる臨床ツールキットが拡大し、ライソゾーム貯蔵障害患者の余命とQOLの両方が向上しています。

どのような市場動向とヘルスケア開拓がライソゾーム病治療エコシステムを形成していますか？

ライソゾーム病治療エコシステムは、市場動向、規制力学、ヘルスケア政策、技術開発の複雑な相互作用によって形成されています。成長の大きな原動力となっているのは、希少疾患や希少疾病に対する世界の関心の高まりであり、これまで十分な治療を受けていなかった患者集団に注目が集まっています。FDAやEMAなどの規制機関は、この分野の技術革新を奨励するため、ファスト・トラック指定、希少疾病用医薬品のステータス、独占販売期間の延長などのインセンティブを提供しています。その結果、バイオ製薬企業はライソゾーム病パイプラインに多額の投資を行い、臨床試験や新たな治療法の承認数が増加しています。新生児スクリーニングプログラムとゲノム配列決定法の進歩により、ライソゾーム病のような進行性疾患の管理には欠かせない早期発見と介入が可能になってきています。ヘルスケアシステムもまた、LSD患者の多面的なニーズに対応するための専門センターや集学的ケアチームを開発することで適応しています。さらに、このような疾患が家族や介護者に与える負担が認識されるようになり、QOLの指標や介護者支援を治療計画に含めるようになっています。遠隔モニタリングや患者登録などのデジタルヘルスツールの台頭は、疾患の追跡やデータ収集を強化し、長期的な転帰の改善に寄与しています。さらに、研究者、臨床医、アドボカシー組織間の世界の協力体制の強化は、知識の交換を加速させ、治療ガイドラインの調和を図っています。このようなシフトは、臨床治療を改善するだけでなく、市場全体をよりダイナミックで包括的な、患者中心のものにしており、持続的なイノベーションと世界のアクセシビリティの基盤を作りつつあります。

世界のライソゾーム病治療市場の成長を促進する中核要因は何か？

世界のライソゾーム病治療市場の成長は、科学の進歩、ヘルスケアインフラの開拓、規制枠組みの新興国市場、利害関係者の優先事項の変化に根ざした、相互に関連するいくつかの要因によって牽引されています。特に遺伝子検査や新生児スクリーニングプログラムによる診断能力の向上により、患者をより早く、より正確に特定できるようになり、有病率データが拡大していることが主な要因です。バイオテクノロジー企業や製薬企業による希少疾患ポートフォリオへの投資の急増も主要な貢献要因であり、ライソゾーム貯蔵障害は遺伝子編集や酵素工学を含む最先端の治療研究の焦点となっています。希少疾病用医薬品の指定、早期承認の道筋、新興国市場での償還支援など、規制当局の好意的な政策が商業的革新を促し、新規治療法の市場参入障壁を低くしています。患者アドボカシーや世界の啓発キャンペーンの高まりもヘルスケア政策に影響を与え、利害関係者間の協力を促し、救命治療への迅速なアクセスを後押ししています。ドラッグデリバリーシステム、バイオマーカー探索、バイオインフォマティクスの技術的進歩は、より効果的で個別化された治療戦略を促進しています。アカデミアと産業界の戦略的パートナーシップは、ベンチからベッドサイドへのトランスレーショナルリサーチを推進し、ヘルスケアプロバイダーは、遺伝カウンセリング、心理社会的サポート、長期モニタリングを含む統合ケアパスをますます構築しています。さらに、ライソゾーム病における未充足の神経学的・全身的ニーズに対応する治療法への需要が、対症療法にとどまらず疾患の根本原因をターゲットとする次世代プラットフォームの開発を促しています。これらの複合的な推進力により、ライソゾーム病治療は、インパクトの大きい治療の焦点であり続けるだけでなく、希少疾患とプレシジョン・メディシンの展望の中で最もダイナミックで有望な分野の一つであることが確実になっています。

セグメント

疾患タイプ（ムコ多糖症、ポンペス症候群、ファブリー病、ゴーシェ病、その他の疾患タイプ）、療法（基質除去療法、幹細胞療法、酵素補充療法、その他の治療法）、投与経路（経口投与、非経口投与、その他の投与経路）、エンドユーザー（病院、専門クリニック、在宅医療、その他のエンドユーザー）

調査対象企業の例

• Alexion Pharmaceuticals（AstraZeneca）
• Amicus Therapeutics, Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• BioMarin Pharmaceutical Inc.
• Chiesi Farmaceutici S.p.A.
• Eli Lilly and Company
• Horizon Therapeutics plc
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Novartis International AG
• Orphazyme A/S
• Pfizer Inc.
• Protalix BioTherapeutics, Inc.
• Raptor Pharmaceuticals
• Recordati Industria Chimica S.p.A.
• Sanofi（Genzyme）
• Sigilon Therapeutics, Inc.
• Shire（Takeda）
• Ultragenyx Pharmaceutical Inc.

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Lysosomal Disease Treatment Market to Reach US$11.2 Billion by 2030

The global market for Lysosomal Disease Treatment estimated at US$8.2 Billion in the year 2024, is expected to reach US$11.2 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Mucopolysaccharidosis Disease, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Pompes Syndrome Disease segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 8.8% CAGR

The Lysosomal Disease Treatment market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Lysosomal Disease Treatment Market - Key Trends & Drivers Summarized

Why Is Lysosomal Disease Treatment Gaining Increasing Importance in Modern Therapeutics?

Lysosomal diseases, also known as lysosomal storage disorders (LSDs), are a group of rare genetic conditions that result from the malfunction or absence of specific enzymes responsible for breaking down various substances in the body’s cells. The accumulation of these substances within the lysosomes leads to progressive cellular damage, impacting vital organs and systems. Historically, the diagnosis and treatment of LSDs were limited, with patients facing a life marked by significant disability and reduced lifespan. However, recent advancements in diagnostics, biotechnology, and therapeutic development have begun to transform the outlook for individuals with these complex conditions. Lysosomal disease treatment is now gaining traction within the rare disease research ecosystem, reflecting a broader shift toward precision medicine and patient-specific care. Increasing public awareness, advocacy from patient groups, and orphan drug incentives have contributed to greater focus and investment in this space. As a result, LSDs have transitioned from being largely untreatable to being among the most actively researched rare disorders in the pharmaceutical landscape. Conditions such as Gaucher disease, Fabry disease, Pompe disease, and various forms of mucopolysaccharidoses (MPS) are now at the forefront of genetic and enzyme replacement research. The urgency to address these life-threatening diseases, combined with the rapid pace of innovation in gene therapy and biologics, is positioning lysosomal disease treatment as a key frontier in the advancement of modern rare disease therapeutics.

How Are Scientific Advances and Treatment Modalities Evolving in Lysosomal Disease Therapy?

The treatment landscape for lysosomal diseases is evolving rapidly, fueled by groundbreaking developments in enzyme replacement therapy (ERT), substrate reduction therapy (SRT), gene therapy, and pharmacological chaperones. ERT has been the most established approach, involving the intravenous infusion of synthetic versions of the deficient enzymes to restore lysosomal function. While effective in alleviating certain symptoms and improving quality of life, ERT often struggles to address neurological manifestations due to its inability to cross the blood-brain barrier. This limitation has spurred innovation in gene therapy, where therapeutic genes are delivered directly into patients’ cells using viral vectors such as AAV (adeno-associated virus). These gene therapies aim to provide a long-term solution by enabling the patient’s own cells to produce the necessary enzymes, offering hope for systemic and central nervous system involvement. Pharmacological chaperones are another emerging option, working by stabilizing the misfolded enzymes and enhancing their function. Meanwhile, substrate reduction therapies aim to decrease the build-up of toxic substrates by limiting their production, offering a complementary strategy to enzyme-focused approaches. Advances in CRISPR gene editing, exosome-based delivery, and nanomedicine are also under investigation as potential future tools to target lysosomal dysfunction more precisely. Importantly, personalized treatment regimens are becoming more viable due to improved diagnostic capabilities, such as next-generation sequencing and biomarker identification, which allow early and accurate identification of LSD subtypes. These evolving treatment modalities are expanding the clinical toolkit available to physicians and researchers, increasing both life expectancy and quality of life for patients with lysosomal storage disorders.

What Market Trends and Healthcare Developments Are Shaping the Lysosomal Disease Treatment Ecosystem?

The lysosomal disease treatment ecosystem is being shaped by a complex interplay of market trends, regulatory dynamics, healthcare policies, and technological developments. A significant driver of growth is the increasing global focus on rare and orphan diseases, which is drawing attention to previously underserved patient populations. Regulatory agencies such as the FDA and EMA are offering incentives like fast-track designations, orphan drug status, and extended exclusivity periods to encourage innovation in this area. As a result, biopharmaceutical companies are investing heavily in lysosomal disease pipelines, leading to a growing number of clinical trials and new therapeutic approvals. Advances in newborn screening programs and genomic sequencing are enabling earlier detection and intervention, which is crucial for managing progressive disorders like LSDs. Healthcare systems are also adapting by developing specialized centers of excellence and multidisciplinary care teams to address the multifaceted needs of LSD patients. Additionally, there is a growing recognition of the burden these diseases place on families and caregivers, prompting the inclusion of quality-of-life metrics and caregiver support in treatment plans. The rise of digital health tools, including remote monitoring and patient registries, is enhancing disease tracking and data collection, contributing to better long-term outcomes. Moreover, increasing global collaboration among researchers, clinicians, and advocacy organizations is accelerating knowledge exchange and harmonizing treatment guidelines. These shifts are not only improving clinical care but are also making the overall lysosomal disease treatment market more dynamic, inclusive, and patient-centered, creating a foundation for sustained innovation and global accessibility.

What Are the Core Drivers Fueling the Growth of the Global Lysosomal Disease Treatment Market?

The growth in the global lysosomal disease treatment market is driven by several interrelated factors rooted in scientific progress, healthcare infrastructure development, evolving regulatory frameworks, and changing stakeholder priorities. A primary driver is the expanding prevalence data due to improved diagnostic capabilities, particularly through genetic testing and newborn screening programs, which are identifying patients earlier and more accurately. The surge in investment by biotechnology and pharmaceutical firms into rare disease portfolios is another key contributor, with lysosomal storage disorders becoming a focal point for cutting-edge therapeutic research, including gene editing and enzyme engineering. Favorable regulatory policies, including orphan drug designations, accelerated approval pathways, and reimbursement support in developed markets, are encouraging commercial innovation and reducing market-entry barriers for new therapies. The rise of patient advocacy and global awareness campaigns is also influencing healthcare policy and encouraging collaboration among stakeholders, pushing for faster access to life-saving treatments. Technological advances in drug delivery systems, biomarker discovery, and bioinformatics are facilitating more effective and personalized treatment strategies. Strategic partnerships between academia and industry are driving translational research from bench to bedside, while healthcare providers are increasingly creating integrated care pathways that include genetic counseling, psychosocial support, and long-term monitoring. Furthermore, the demand for therapies that address unmet neurological and systemic needs in lysosomal diseases is prompting the development of next-generation platforms that go beyond symptom management to target the root causes of disease. These combined drivers are ensuring that lysosomal disease treatment not only remains a high-impact therapeutic focus but also represents one of the most dynamic and promising areas within the rare disease and precision medicine landscape.

SCOPE OF STUDY:

The report analyzes the Lysosomal Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease, Other Disease Types); Therapy (Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy, Other Therapies); Administration Route (Oral Administration, Parenteral Administration, Other Administration Routes); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Alexion Pharmaceuticals (AstraZeneca)
• Amicus Therapeutics, Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• BioMarin Pharmaceutical Inc.
• Chiesi Farmaceutici S.p.A.
• Eli Lilly and Company
• Horizon Therapeutics plc
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Novartis International AG
• Orphazyme A/S
• Pfizer Inc.
• Protalix BioTherapeutics, Inc.
• Raptor Pharmaceuticals
• Recordati Industria Chimica S.p.A.
• Sanofi (Genzyme)
• Sigilon Therapeutics, Inc.
• Shire (Takeda)
• Ultragenyx Pharmaceutical Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Lysosomal Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advancements in Enzyme Replacement Therapies (ERTs) Throw the Spotlight on Standard-of-Care Evolution
  • Growing R&D Focus on Gene Therapy and Genome Editing Propels Growth in Curative Treatment Pathways
  • Expanded Newborn Screening Programs Drive Earlier Diagnosis and Broaden the Treatable Patient Population
  • Orphan Drug Designation Incentives Generate Opportunities for Niche Biotech Innovation and Market Entry
  • Increased NIH and Global Funding for Rare Diseases Spurs Clinical Pipeline Activity Across Lysosomal Disorders
  • Here's How Improved Disease Awareness and Advocacy Accelerate Demand for Early Intervention Therapies
  • Emergence of Substrate Reduction Therapies Expands the Addressable Market for Non-ERT Treatment Modalities
  • Personalized and Precision Medicine Approaches Drive Adoption of Genotype-Targeted Therapeutic Development
  • Innovations in Drug Delivery Systems Propel Growth in CNS-Penetrating and Oral Formulations
  • High Unmet Need in Neuropathic and Advanced Disease Subtypes Generates Demand for Next-Generation Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Lysosomal Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Lysosomal Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Lysosomal Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Mucopolysaccharidosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Mucopolysaccharidosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Mucopolysaccharidosis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Pompes Syndrome Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Pompes Syndrome Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Pompes Syndrome Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Fabry Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Fabry Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Fabry Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Gaucher's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Gaucher's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Gaucher's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Homecare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Substrate Reduction Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Substrate Reduction Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Substrate Reduction Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: USA 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: USA 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Canada 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Canada 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• JAPAN
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Japan 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Japan 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• CHINA
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 89: China Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: China 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: China 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: China 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: China 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• EUROPE
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Lysosomal Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Lysosomal Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Europe 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Europe 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• FRANCE
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 116: France Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: France 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: France 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: France 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: France 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• GERMANY
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Germany 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Germany 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Italy 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Italy 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 152: UK Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: UK 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: UK 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Spain 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Spain 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Russia 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Russia 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Lysosomal Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Lysosomal Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Australia 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Australia 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• INDIA
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 227: India Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: India 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: India 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: India 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: India 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: South Korea 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: South Korea 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Lysosomal Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Lysosomal Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Latin America 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Latin America 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Argentina 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Argentina 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Brazil 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Brazil 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Mexico 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Mexico 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Lysosomal Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Lysosomal Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Middle East 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Middle East 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Iran 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Iran 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Israel 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: Israel 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: UAE 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: UAE 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030
• AFRICA
  • Lysosomal Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Lysosomal Disease Treatment by Disease Type - Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Lysosomal Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Mucopolysaccharidosis Disease, Pompes Syndrome Disease, Fabry Diseases, Gaucher's Disease and Other Disease Types for the Years 2014, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Lysosomal Disease Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Lysosomal Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Lysosomal Disease Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 409: Africa 16-Year Perspective for Lysosomal Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Lysosomal Disease Treatment by Therapy - Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 412: Africa 16-Year Perspective for Lysosomal Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy and Other Therapies for the Years 2014, 2025 & 2030

IV. COMPETITION